Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. - Wikidata - awgldk - TriplyDB

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

http://www.wikidata.org/entity/Q34150929

about

Predictors of delayed culture conversion among Ugandan patients.Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis Ethnic variation in inflammatory profile in tuberculosis.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.Role of pharmacogenomics in the treatment of tuberculosis: a review A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses Pharmacokinetics of anti-tuberculosis drugs in children.Pharmacologic considerations in use and development of antituberculosis drugs.Human genetic factors in tuberculosis: an update.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?The challenges of pharmacokinetic variability of first-line anti-TB drugs.Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics.Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults.The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.Relationship between CES2 genetic variations and rifampicin metabolism.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.

P2860

Q33595569-098A40A6-BB1F-480D-877B-A7D8F5F06791 Q33797850-F6B975BF-5D65-419A-BEB3-AD6968D4B0DF Q33797999-8BA28B13-A1D5-4F30-8F7E-E8899F24AC9F Q33843657-9DF334D2-BE7A-4797-B0C2-4795868FD22F Q33873368-8D12F276-A0CC-4E33-9A5F-F59D8B5EEAFB Q34057466-77831D4F-2B28-4836-9704-BB66E6FD446A Q34058356-8A308A48-45B2-4173-A0E4-475A4EE00A19 Q34596844-3016D3CF-609A-497C-BA2F-AD87C92D47B6 Q34819594-2610515D-1974-46A9-AE34-3FBAD2A0CB47 Q35191432-3CF8B212-C3C5-42F8-B91E-BC3D29A67324 Q35584822-5E41C0E1-25D9-4321-AA51-DCD946634D53 Q35617587-228EB092-7E3F-45A0-B515-6369399E2CA2 Q36000004-F2E41DD6-8B2F-4B5D-8912-96BAF6C6FE8A Q36036963-689615C4-7A96-4CF8-A516-1FEAD782424E Q36086369-8980ED28-9B4A-4C77-9050-E12031C40593 Q36171524-AEE1C105-C7E3-4A6E-85E0-AF098A71F746 Q36439164-6D9DDAEA-A85A-4A51-AFA2-B3BB4C2DE78C Q36441540-24FA9F3C-B62A-4CDF-A35C-F090E7229211 Q36706812-E23D6F25-882B-4167-8A5E-91FC7C016027 Q36981855-1A67E76C-0D54-48DD-B05E-002C64208761 Q37334396-82076FFA-92AB-46F3-AF1C-ED683E73BAA9 Q37626582-4DA250C7-50DF-44EA-BCDA-518BEAB4E3E5 Q37688266-7025D4C1-3E29-4372-9271-D42078A3F1D4 Q37821811-C0441DC0-6127-419B-81E3-D9417A11B6FB Q38252559-00728FF1-EC75-4FB6-AB9C-B87B0AEE21C8 Q38689735-515F6636-1293-4BB4-86D2-69C4C06D2C36 Q38865905-C01842FA-B9DF-42EB-B823-62BC76D43685 Q38888369-D33B49C9-A726-4F01-9D55-D9F2B4E371D3 Q38977166-C9026ED9-905B-43F9-ADB4-4A03C5FE7A4A Q40180361-03061A67-6363-4465-88C7-8E961E34AEC6 Q40226194-B69E10A9-FB14-42B8-AA8C-10E15B39406A Q40500659-9AD13937-8801-4772-B89E-A2EBC6F94293 Q40571190-FCC9FA2D-805B-4993-822C-7A3D4F050487 Q42717214-F12ED347-5330-4654-AF0D-539BCEFE5762 Q42881940-0977A6A8-82BA-4FD5-A06A-3B151F4F7196 Q43940364-F370BE1F-3DC2-4E8F-9AFA-CE01575443AA Q45151120-7F3677D6-49DF-4A48-8AE2-05E72EA25A35 Q47332682-036F5D9D-30C6-4804-A935-6B39E475BB91 Q49792134-FA110BC6-88ED-4D98-9A16-96146811B2A6 Q50124934-BE7CE2C9-6607-4F52-9B1F-4FFF8A3E36B0

P2860

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

http://www.wikidata.org/entity/Q34150929

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@ast

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@en

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@nl

type

label

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@ast

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@en

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@nl

prefLabel

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@ast

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@en

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@nl

P1433

Q34150929-240DF637-2CF6-4E7F-8793-CBDB2915A826

P1476

Q34150929-06992C1B-E8FC-4ADB-B26A-6521555420DB

P2093

Q34150929-14561294-ECAF-4290-9A65-4581A65F2402

Q34150929-33240ED2-98C2-4F5C-B44C-895BC4F194FD

Q34150929-35C3B881-67E3-4AEA-83C2-3CF48D73E4AA

Q34150929-4273CA51-1928-4B92-9722-1F6B1ED11209

Q34150929-4F9FCA5A-C71A-4870-9BE0-19AABDD3B04B

Q34150929-71C95DD6-C6FA-45DC-8F7D-C04C6EE693E4

Q34150929-71FED291-DE95-4F35-A424-6E5B9C74C359

Q34150929-7BE0EAA7-A0F7-4B30-8CD7-671CB19A982C

Q34150929-8591EBB3-B816-4E80-9CD8-7B43C747FCB3

Q34150929-8A5C1095-2288-47EF-9D2C-95E347DBE580

P2860

Q34150929-056D95F1-D3F1-41D1-8ECB-FD0BB9167253

Q34150929-0A71AD68-A93F-4C29-8735-CEE9C358E148

Q34150929-1CD111C7-9096-42DD-859A-99DF6BD27252

Q34150929-212772A2-6E88-4176-92BF-41C896C18226

Q34150929-2D5B4AA8-53D1-41F0-A813-0A122B099192

Q34150929-3027F2DE-590E-4D95-9AE9-1A26C0DD34C1

Q34150929-3761CDE7-8BFA-4985-821D-E1035ED6D9B9

Q34150929-4281E29B-DA46-4A2E-8641-D1508E39100A

Q34150929-44466AB3-A62B-422F-8DC7-131224B98FEC

Q34150929-55087412-C2EB-44C1-9C02-09824437A31C

P304

Q34150929-9089FBD6-8056-4677-959F-A39A70A7106D

P31

Q34150929-71FCF4F5-9DA3-4C46-82B0-020EFC18FE82

P356

Q34150929-3A30C317-6055-4318-A760-50F53263B04F

P407

Q34150929-BB6627D9-E9F0-4AD5-B2D2-02B15E1B9F57

P433

Q34150929-C77341E7-350A-43A3-89E2-CD82E07C618C

P478

Q34150929-E7EA78C8-5089-4FC0-9190-B962CEAB257E

P577

Q34150929-C27E0115-21E1-4DA8-9775-EC6923616F58

P698

Q34150929-7BA94D9E-C349-44BD-9F6A-BC5FEFB69B02

P921

Q34150929-F0A0D2C1-2B54-4F7D-9E4A-F30240AF7B4D

P932

Q34150929-52F8446A-0CF8-44DC-B0BB-7D1F76CE8F24

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Effects of tuberculosis, race, ...... ms on rifampin concentrations.

@en

P2093

Andrew Vernon

http://www.w3.org/2001/XMLSchema#string

Charles Peloquin

http://www.w3.org/2001/XMLSchema#string

Chi-Cheng Luo

http://www.w3.org/2001/XMLSchema#string

Erin Bliven-Sizemore

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Marc Weiner

http://www.w3.org/2001/XMLSchema#string

Melissa Engle

http://www.w3.org/2001/XMLSchema#string

Thomas J Prihoda

http://www.w3.org/2001/XMLSchema#string

William Burman

http://www.w3.org/2001/XMLSchema#string

William R Mac Kenzie

http://www.w3.org/2001/XMLSchema#string

P2860

Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation

Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.

Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis.

P304

4192-4200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00353-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20660695

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2944564

http://www.w3.org/2001/XMLSchema#string